Need professional-grade analysis? Visit stockanalysis.com
$2.31B
N/A
N/A
N/A
Immunome Inc (IMNM) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $24.63, up 5.89% from the previous close.
Over the past year, IMNM has traded between a low of $7.43 and a high of $26.97. The stock has gained 200.7% over this period. It is currently 8.7% below its 52-week high.
Immunome Inc has a market capitalization of $2.31B.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Side-by-side comparison against top Healthcare peers.